

## Previous Seminars

### 2019 – 2020

9 December	<p><i>“Ethics, markets and organizations” (joint work with Jean Tirole)</i></p> <p>Mathias Dewatripont, Co-director at I3h Institute and Professor at ULB, Former Executive Director of the National Bank of Belgium and Dean of the Solvay Brussels School of Economics and Management</p>
25 November	<p><i>A new year, a new you? A two-selves model of within-individual variation in food purchases</i></p> <p>Bram De Rock, Professor in Mathematical Economics at ULB and KU Leuven; Director of ECARES</p>
4 November	<p><i>The importance of social network in health, health care and in health policies</i></p> <p>Vincent Lorant, Professor at Faculty of Public Health, UCL</p>
30 September	<p><i>Vaccines hesitancy</i></p> <p>Marie Neunez, Research fellow at I3h Institute</p>

### 2018 – 2019

03 June	<p><i>Effects of physician-industry interactions on treatments: the case of heart attacks</i></p> <p>Sofia Amaral-Garcia, Postdoc Researcher at Hasselt University in the research group Economics and Public Policy</p>
16 May	<p><i>Opioid analgesics consumption in France</i></p> <p>Ilaria Natali, Teaching Assistant for Advanced Industrial Organization, ULB</p>
29 April	<p><i>Market access of pharmaceutical innovation: international R&amp;D, high prices and national competent authorities</i></p> <p>Philippe Van Wilder, Professor in health economics and HTA at Ecole de Santé Publique, ULB</p>
18 February	<p><i>Subsidized Health Insurance and Healthcare Utilization: new evidence from a large-scale field experiment</i></p> <p>Raf Van Gestel, Assistant Professor, Erasmus School of Economics &amp; Erasmus School of Health Policy and Management</p>
21 January	<p><i>Therapeutic drug monitoring of biologics: where to start, where to end?</i></p> <p>Lynda Grine, Doctor-assistant at Ghent University and Research Associate at the Dermatology Department of Ghent University Hospital</p>
10 December	<p><i>Scientific, regulatory, and economic challenges facing the implementation of phage therapy and the Belgian model</i></p>

Bob Blasdel, Research Director for Vesale Pharma

30 November

*The case of a multi-drug resistant infection*

[Link to program](#)

26 November

*Precision oncology: how to structure the continuum of clinical research into healthcare for rationale access to anti-cancer treatment*

Denis Lacombe, Director General of the European Organisation for Research and Treatment of Cancer

12 November

*Market definition in the pharmaceutical industry: a case of drugs hopping antitrust markets*

Georges Siotis, Associate Professor at the Economics Department of Universidad Carlos III de Madrid and CEPR Research Fellow

29 October

*Towards new partnerships in the healthcare sector*

Wim Van Haverbeke, Professor of Innovation Management & Strategy at the Hasselt University

08 October

*Vaccines: how to value them, how to price them?*

Michel Dewilde, MDWConsultant, former Senior Vice President R&D, Sanofi Pasteur

01 October

*Measuring mortality in conflicts and disasters: why does it matter?*

Debarati Guha, Director of the Centre for Research on the Epidemiology of Disasters (CRED) and Professor at the School of Public Health (UCL)